PREVENTION OF THROMBOEMBOLISM WITH RIVAROXABAN IN GENITOURINARY CANCER PATIENTS RECEIVING SYSTEMIC THERAPY: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL
- Registry ID
- PGU2023
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- OTTAWA HOSPITAL RESEARCH INSTITUTE
- Start date
- 2024-10-01
- Last update
- 2023-06-29
Conditions
Related clinical trials
- ProActIF-01 Trial: Feasibility Study of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Digestive Cancers
- VEDOLIZUMAB FOR THE PREVENTION OF IMMUNE CHECKPOINT INHIBITOR RELATED TO DIARREA OR COLITIS IN PATIENTS WITH CANCER. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL
- TRIPTORELIN AND PROTECTION OF OVARIAN RESERVE IN ADOLESCENTS AND YOUNG ADULTS WITH CANCER
- OPTIMAL PRECISION THERAPIES TO CUSTOMISE CARE IN CHILDHOOD AND
ADOLESCENT CANCER (OPTIMISE)
- AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS
PREVIOSULY ENROLLED IN A GENENTECH AND/OR F.HOFFMANLA ROCHE SPONSORED STUDY
- A PHASE 3, MULTICENTER, DOA PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF IVOSIDENIB IN PARTICIPANTS = 18 YEARS OF AGE WITH LOCALLY ADVANCED OR METASTATIC CONVENTIONAL CHONDROSARCOMA WITH AN IDH1 MUTATION, UNTREATED OR PREVIOUSLY
View on source registry